West Pharmaceutical Services (MEX:WST) Cyclically Adjusted Revenue per Share: MXN761.25 (As of Mar. 2026)


MEX:WST West Pharmaceutical Services Inc MEX:WST
95 GF Score
Price MXN5,112.51
GF Value MXN5,236.25
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Cyclically Adjusted Revenue per Share?

West Pharmaceutical Services MEX:WST 95 Cyclically Adjusted Revenue per Share is MXN761.25 as of Mar. 2026. GuruFocus rates MEX:WST with a GF Score™ of 95/100 and a GF Value™ of MXN5,236.25. The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

West Pharmaceutical Services's adjusted revenue per share for the three months ended in Mar. 2026 was MXN210.440. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN761.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, West Pharmaceutical Services's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of West Pharmaceutical Services was 11.90% per year. The lowest was 2.10% per year. And the median was 6.70% per year.

As of today (2026-07-09), West Pharmaceutical Services's current stock price is MXN5112.51. West Pharmaceutical Services's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN761.25. West Pharmaceutical Services's Cyclically Adjusted PS Ratio of today is 6.72.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of West Pharmaceutical Services was 19.19. The lowest was 3.99. And the median was 8.00.


West Pharmaceutical Services  (MEX:WST) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

West Pharmaceutical Services's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5112.51/761.25
=6.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of West Pharmaceutical Services was 19.19. The lowest was 3.99. And the median was 8.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


West Pharmaceutical Services Cyclically Adjusted Revenue per Share Related Terms


West Pharmaceutical Services Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for West Pharmaceutical Services's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services Cyclically Adjusted Revenue per Share Chart

West Pharmaceutical Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 527.87 831.80 590.02 657.40 671.53

West Pharmaceutical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 690.84 661.65 604.90 671.53 761.25

MEX:WST vs RMD, MDLN, COO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


West Pharmaceutical Services Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Cyclically Adjusted PS Ratio falls into.


MEX:WST
95GF Score
West Pharmaceutical Services Inc MEX:WST
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

West Pharmaceutical Services Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, West Pharmaceutical Services's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=210.44/330.2130*330.2130
=210.440

Current CPI (Mar. 2026) = 330.2130.

West Pharmaceutical Services Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 95.929 241.018 131.430
201609 97.116 241.428 132.830
201612 103.846 241.432 142.033
201703 97.463 243.801 132.007
201706 94.816 244.955 127.817
201709 95.211 246.819 127.380
201712 110.002 246.524 147.345
201803 100.030 249.554 132.361
201806 117.242 251.989 153.637
201809 106.670 252.439 139.534
201812 110.024 251.233 144.612
201903 114.250 254.202 148.413
201906 120.139 256.143 154.880
201909 119.263 256.759 153.382
201912 117.246 256.974 150.662
202003 152.645 258.115 195.283
202006 161.177 257.797 206.452
202009 159.708 260.280 202.619
202012 151.065 260.474 191.511
202103 180.868 264.877 225.482
202106 190.277 271.696 231.258
202109 191.145 274.310 230.099
202112 192.694 278.802 228.227
202203 188.631 287.504 216.652
202206 204.710 296.311 228.132
202209 182.523 296.808 203.066
202212 183.004 296.797 203.608
202303 170.630 301.836 186.672
202306 171.394 305.109 185.496
202309 172.894 307.789 185.490
202312 166.334 306.746 179.059
202403 155.330 312.332 164.223
202406 174.526 314.175 183.435
202409 200.364 315.301 209.840
202412 212.762 315.605 222.610
202503 195.614 319.799 201.984
202506 199.070 322.561 203.792
202509 203.302 324.800 206.690
202512 199.375 324.054 203.164
202603 210.440 330.213 210.440

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN761.25 mean?
West Pharmaceutical Services (MEX:WST) has a Cyclically Adjusted Revenue per Share of MXN761.25 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on West Pharmaceutical Services and its competitors.
Is West Pharmaceutical Services' Cyclically Adjusted Revenue per Share too high?
West Pharmaceutical Services' current Cyclically Adjusted Revenue per Share is MXN761.25. Overall, West Pharmaceutical Services has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Cyclically Adjusted Revenue per Share compare to RMD and MDLN?
West Pharmaceutical Services' Cyclically Adjusted Revenue per Share of MXN761.25 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current Cyclically Adjusted Revenue per Share is MXN761.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
West Pharmaceutical Services (MEX:WST) has a current Cyclically Adjusted Revenue per Share of MXN761.25. The stock's GF Value™ is MXN5,236.25, compared to a current price of MXN5,112.51 — trading 2.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN761.25. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For West Pharmaceutical Services (MEX:WST), the current Cyclically Adjusted Revenue per Share is MXN761.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (MEX:WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of MXN5,112.51 is trading 2.4% below its estimated GF Value™ of MXN5,236.25.

Key valuation signals for MEX:WST:

  • Cyclically Adjusted Revenue per Share: MXN761.25
  • GF Value™: MXN5,236.25 vs. price of MXN5,112.51 (2.4% below fair value)
  • GF Score™: 95/100 with 9 warning signs

No single metric tells the full story. See the MEX:WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for MEX:WST

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN5,112.51
Price
MXN5,236.25
GF Value